Market Overview

Global Biosimilars and Biologics Market reached US$ 19.5 billion in 2023 and is expected to reach US$ 91.98 billion by 2033, growing at a CAGR of 21.4% during the forecast period 2025-2033.

Download Free Sample: 

https://www.datamintelligence.com/download-sample/biosimilars-and-biologics-market?ch

Market Dynamics

The growing aging population and rising chronic disease burden are driving the biosimilars and biologics market. As conditions like cancer, diabetes, and autoimmune disorders increase, demand for targeted biologic therapies rises. The National Institute of Health reports a 19.1% annual increase in autoimmune diseases, while cancer cases are projected to reach 29.9 million by 2040. With the global population over 60 expected to nearly double by 2050, healthcare systems face financial strain, accelerating the adoption of cost-effective biosimilars as patents for original biologics expire.

Market Segment

By Type: Biologics, Biosimilars

By Application: Oncology, Autoimmune Diseases, Chronic Diseases, Infectious Diseases, Neurology, Ophthalmology, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Customize Your Sample: 

https://www.datamintelligence.com/customize/biosimilars-and-biologics-market

Market Geographical Size:

North America, particularly the U.S. and Canada, is expected to lead the biosimilars and biologics market, driven by aging populations and rising chronic disease prevalence. With 129 million Americans affected by major chronic conditions and 50 million facing autoimmune diseases, demand for biologics and cost-effective biosimilars is growing. The FDA's streamlined approval process, including the Biologics Price Competition and Innovation Act, accelerates market entry. Biosimilars are projected to save $133 billion over the next five years, expanding patient access and reducing healthcare costs.

Market Key Players:

Amgen Inc., 

Johnson & Johnson

Biogen Inc., 

Teva Pharmaceutical Industries Limited

Biocon Biologics Inc. 

Pfizer Inc., 

Celltrion, Inc., 

Samsung Bioepis

AbbVie Inc.

Boehringer Ingelheim International GmbH

Key Development

In October 2024, Fresenius Kabi launched Tyenne, Canada's first approved biosimilar of tocilizumab. Tyenne expands treatment options for inflammatory and immune diseases, including rheumatoid arthritis, giant cell arteritis, and systemic juvenile idiopathic arthritis, improving patient access to care